X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

GLSI

Closed

Greenwich Lifesciences inc

9.05
-0.02 (-0.22%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 9.07
Day's Range: 8.97 - 9.6
Send
When Written:
 
13.31
Greenwich Lifesciences Inc. is a clinical-stage biopharmaceutical company that is focused on the development of immunotherapy treatments for breast cancer. The company's lead product candidate is GP2, a peptide-based immunotherapy that is designed to prevent the recurrence of breast cancer in patients who have previously undergone surgery. GP2 is currently in Phase III clinical trials and has received Fast Track and Orphan Drug designations from the FDA. Greenwich Lifesciences was founded in 2016 and is headquartered in Stafford, Texas.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X